Home / Business and Economy / Wockhardt Antibiotic Miqnaf Gains Wider Indian Access
Wockhardt Antibiotic Miqnaf Gains Wider Indian Access
2 Nov
Summary
- Miqnaf's marketing access expanded in India post-supply condition removal.
- Zaynich, an Indian-developed drug, secured US FDA approval.
- Wockhardt's biotech business saw a 68% revenue increase.
Wockhardt's novel antibiotic, Miqnaf (nafithromycin), is now accessible to a broader patient population in India. This expansion follows the Drugs Controller General of India's decision to remove a previously imposed supply condition.
The company has reported strong clinical acceptance for Miqnaf, highlighting its broad pathogen coverage and shorter therapy duration. Wockhardt also announced plans to seek an additional indication for Miqnaf in the third or fourth quarter of FY27 for upper respiratory tract infections.
In a significant achievement for Indian pharmaceuticals, Wockhardt's antibiotic Zaynich received approval from the US Food and Drug Administration on May 29 for complicated urinary tract infections. This marks the first drug discovered and developed in India to gain US FDA approval.
Wockhardt's biotechnology operations demonstrated robust growth, with revenue climbing 68% year-on-year to Rs 252 crore in the second quarter. For the first half of FY27, revenue in this segment grew by 87% to Rs 487 crore.
Overall, Wockhardt's consolidated revenue saw a 24% year-on-year increase, reaching Rs 969 crore in the second quarter of FY27, though profit after tax declined slightly to Rs 73 crore from Rs 82 crore in the prior year's corresponding quarter.
